drugset / Trial / NCT07518771

PA-001 Ph.1 Study in Healthy and Elderly Subjects

NCT07518771

Phase 1 Completed 47 enrolled PeptiDream Inc. PeptiAID Inc. · collab
RandomizedSequentialTriple-blindTreatment

Summary

This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts. The principal aim of this study was to obtain safety and tolerability data when PA-001 is administered IV as single and multiple doses to healthy subjects. This information, together with the PK data, will help establish the doses and dosing regimen suitable for future studies in patients. The study also investigated the effects of age on the PK of PA-001 prior to patient studies.

Timeline

Start
2024-07-30
Primary completion
2025-06-02
Completion
2025-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PA-001 Unknown Intravenous

Indications